資料2

アンチバイオグラム
地域別2025

Escherichia coli 大腸菌
Klebsiella pneumoniae subsp. pneumoniae
クレブシエラ菌
Streptococcus pneumoniae 肺炎球菌（髄液検体以外）
Streptococcus pyogenes 溶連菌
Haemophilus influenzae インフルエンザ菌
Staphylococcus aureus 黄色ブドウ球菌 (耐性比率)

全国データは、JANIS （Japan Nosocomial Infections Surveillance 厚生労働省院内感染対策サーベイランス事業）の資料に基づいたものです

S：感受性、I：中間、R：耐性、NS：非感受性

腸内細菌目細菌の固有耐性

CLSI M100-ED35:2025 Performance Standards for Antimicrobial Susceptibility Testing, 35th Edition **より引用**

Antimicrobial Agent → / Organism ↓	Ampicillin	Amoxicillin-Clavulanate	Ampicillin-Sulbactam	Ticarcillin	Cephalosporins I: Cefazolin, Cephalothin	Cephamycins: Cefoxitin, Cefotetan	Cephalosporins II: Cefuroxime	Imipenem	Tetracyclines	Tigecycline	Nitrofurantoin	Polymyxin B Colistin	Aminoglycosides
Citrobacter freundii	R	R	R		R	R	R						
Citrobacter koseri, Citrobacter amalonaticus group[a]	R			R									
Enterobacter cloacae complex[b]	R	R	R		R	R							
Escherichia coli	There is no intrinsic resistance to β-lactams in this organism.												
Escherichia hermannii	R			R									
Hafnia alvei	R	R	R		R	R						R[c]	
Klebsiella (formerly *Enterobacter*) *aerogenes*	R	R	R		R	R							
Klebsiella pneumoniae, Klebsiella oxytoca, Klebsiella variicola	R			R									
Morganella morganii	R	R			R		R	d		R	R	R	
Proteus mirabilis	There is no intrinsic resistance to penicillins and cephalosporins in this organism.							d	R	R	R	R	
Proteus penneri	R				R		R	d	R	R	R	R	
Proteus vulgaris	R				R		R	d	R	R	R	R	
Providencia rettgeri	R	R			R			d	R	R	R	R	
Providencia stuartii	R	R			R			d	R	R	R	R	e
Raoultella spp.[f]	R			R									
Salmonella and *Shigella* spp.	There is no intrinsic resistance to β-lactams in these organisms; refer to **WARNING** below for reporting.												
Serratia marcescens	R	R	R		R	R	R				R	R	
Yersinia enterocolitica	R	R		R	R								

Abbreviations: AST, antimicrobial susceptibility testing; MIC, minimal inhibitory concentration; R, resistant.

WARNING: For *Salmonella* and *Shigella* spp., aminoglycosides, first- and second-generation cephalosporins, and cephamycins may appear active *in vitro* but are not effective clinically and should not be reported as susceptible.

Footnotes

a. *C. amalonaticus* group includes *C. amalonaticus, Citrobacter farmeri,* and *Citrobacter sedlakii.*

b. *E. cloacae* complex includes *Enterobacter asburiae, E. cloacae,* and *Enterobacter hormaechei.* Other members of the complex include *Enterobacter kobei* and *Enterobacter ludwigii,* for which AST data are not available.

c. Colistin and polymyxin B resistance also applies to *Hafnia paralvei.*

d. *Proteus*, *Providencia*, and *Morganella* spp. may have elevated MICs to imipenem by mechanisms other than by production of carbapenemases. Isolates that test as susceptible should be reported as susceptible.

e. *P. stuartii* should be considered resistant to gentamicin, netilmicin, and tobramycin but not intrinsically resistant to amikacin.

f. *Raoultella* spp. include *Raoultella ornithinolytica, Raoultella terrigena,* and *Raoultella planticola.*

NOTE 1: Cephalosporins III, cefepime, cefiderocol, aztreonam, ticarcillin-clavulanate, piperacillin-tazobactam, imipenem-relebactam, ceftazidime-avibactam, meropenem-vaborbactam, and carbapenems are not listed because there is no intrinsic resistance in Enterobacterales.

NOTE 2: Enterobacterales are also intrinsically resistant to clindamycin, daptomycin, fusidic acid, glycopeptides (vancomycin), lipoglycopeptides (oritavancin, teicoplanin, telavancin), linezolid, tedizolid, quinupristin-dalfopristin, rifampin, and macrolides (erythromycin, clarithromycin, and azithromycin). However, there are some exceptions with macrolides (eg, *Salmonella* and *Shigella* spp. with azithromycin).

【データ収集期間】

2025年1月から3月までの3ヶ月間（入院・外来検体）の菌株数

JANISデータは2024年（外来検体）と比較した

【データ提供医療機関数（カッコ内はクリニック）】

東部	32施設（10施設）	10123株（17株）
中部	27施設（13施設）	12839株（57株）
西部	28施設（7施設）	11373株（8株）
合計	87施設（30施設）	34335株

【分離菌上位菌種（赤字はアンチバイオグラム作成対象）】

	菌名_2025	西部	中部	東部	総計
1	Escherichia coli	1964	2228	1920	6112
2	Staphylococcus aureus (MSSA)	1171	1462	1074	3707
3	Klebsiella pneumoniae subsp. pneumoniae	760	1034	839	2633
4	Pseudomonas aeruginosa	900	976	685	2561
5	Staphylococcus aureus (MRSA)	715	828	591	2134
6	Enterococcus faecalis	484	574	590	1648
7	Streptococcus agalactiae	400	398	369	1167
8	Staphylococcus epidermidis	414	301	334	1049
9	Klebsiella oxytoca	206	273	264	743
10	Haemophilus influenzae	325	266	108	699
11	Enterococcus faecium	232	277	179	688
12	Proteus mirabilis	175	251	216	642
13	Enterobacter cloacae	137	281	205	623
14	Corynebacterium spp.	164	212	200	576
15	Staphylococcus ,coagulase negative (CNS)	41	223	247	511
16	Streptococcus pneumoniae	219	185	97	501
17	Serratia marcescens subsp. marcescens	142	179	156	477
18	Klebsiella aerogenes	123	167	159	449
19	Streptococcus spp.	260	69	81	410
20	α-Streptococcus	51	185	90	326
21	Streptococcus anginosus	164	88	61	313
22	Staphylococcus aureus subsp. aureus	121	103	70	294
30	G群β-Streptococcus	10	92	67	169
33	Streptococcus pyogenes	54	37	47	138

【*Escherichia coli*】 大腸菌

S:感受性、I:中間、R:耐性、NS:非感受性







【*Escherichia coli*】 大腸菌

S:感受性、I:中間、R:耐性、NS:非感受性







【*Escherichia coli*】 大腸菌

S:感受性、I :中間、R:耐性、NS:非感受性





CLSI M100-ED33:2023 Performance Standards for Antimicrobial Susceptibility Testing, 33rd Editionでは、大腸菌に対するFOMの判定基準は、UTIのみに設定されています。

【 *Klebsiella pneumoniae subsp. pneumoniae*】 クレブシエラ菌

S:感受性、I :中間、R:耐性、NS:非感受性







【 *Klebsiella pneumoniae* 】　クレブシエラ菌

S：感受性、I：中間、R：耐性、NS：非感受性







【 *Streptococcus pneumoniae*（髄液検体以外）】 肺炎球菌

S：感受性、I：中間、R：耐性、NS：非感受性







【 *Streptococcus pneumoniae* (髄液検体以外)】肺炎球菌

S:感受性、I :中間、R:耐性、NS:非感受性







【 *Streptococcus pyogenes* 】溶連菌

S:感受性、I:中間、R:耐性、NS:非感受性







【 *Streptococcus pyogenes*】溶連菌

S：感受性、I：中間、R：耐性、NS：非感受性







【 *Haemophilus influenzae* 】インフルエンザ菌

S：感受性、I ：中間、R：耐性、NS：非感受性







【 *Haemophilus influenzae* 】インフルエンザ菌

S：感受性、I：中間、R：耐性、NS：非感受性







【 *Haemophilus influenzae* 】インフルエンザ菌

S：感受性、I ：中間、R：耐性、NS：非感受性



【 *Staphylococcus aureus* 】 黄色ブドウ球菌
静岡県2025年1−3月期とJANIS2024年との比較



【 バンコマイシン耐性MRSA 患者数】
なし

【 VCM非感受性*Enterococcus faecium* 患者数】
E. faecium

東部	26名	10施設
中部	2名	2施設
西部	11名	1施設